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Background: Patients with previous coronary artery bypass grafting (CABG) who underwent percutaneous
coronary intervention (PCI) have an increased repeat revascularization rate, but data on contemporary second-
generation drug-eluting stents (DES) are scarce.
Methods:We evaluated 1-year clinical outcome following secondary revascularization by PCI in patients of the
TWENTE trial and non-enrolled TWENTE registry, and compared patients with previous CABG versus patients
without previous CABG.
Results: Of all 1709 consecutive patients, 202 (11.8%) had previously undergone CABG (on average 11.2 ±
8.5 years ago). CABG patients were older (68.5 ± 9.4 years vs. 64.1 ± 10.7 years, P b 0.001) and more often
had diabetes (28.7% vs. 20.9%, P = 0.01) and previous PCI (40.1% vs. 19.8%, P b 0.001) compared to patients
without previous CABG. Nevertheless, a higher target vessel revascularization (TVR) rate following PCI in the
CABG patients (9.4% vs. 2.3%, P b 0.001) was the only signiﬁcant difference in clinical outcome at 1-year
follow-up (available for 99.6%). Among CABG patients, the TVR rate was signiﬁcantly higher in patients treated
for graft lesions (n = 65; 95.4% in vein grafts) than in patients treated for native coronary lesions only (n =
137) (18.5% vs. 5.1%, P = 0.002). Among 1638 patients with PCI of native coronary lesions only, there was
only a non-signiﬁcant difference in TVR between patients with previous CABG versus patients without previous
CABG (5.1% vs. 2.3%, P = 0.08).
Conclusions: Patientswith previous CABG showed a favorable safety proﬁle after PCIwith second-generationDES.
Nevertheless, their TVR rate was still much higher, driven by more repeat revascularizations after PCI of
degenerated vein grafts. In native coronary lesions, there was no such difference.© 2014 Elsevier Ireland Ltd. All rights reserved.1. Introduction
In patients with previous coronary artery bypass graft surgery
(CABG), progression of atherosclerosis and degeneration of bypass
grafts may lead to secondary revascularizations — in the majority of
patients by means of percutaneous coronary intervention (PCI) [1,2].
So far, most PCI studies with comprehensive assessment of patientsneous coronary intervention;
ssel revascularization; Non-ST-
coronary artery bypass grafting.
horaxcentrumTwente,Medisch
de, The Netherlands. Tel.: +31
).
.with a history of CABG were performed in the era of bare metal and
early generation drug-eluting stents (DES) [3–5], while only limited
data are available from second-generation DES.
Second-generation DES with more bio-compatible coatings have
been shown to be safe and efﬁcacious in several randomized clinical
trials with limited exclusion criteria. An example of such a trial is the
randomized TWENTE trial, which studied a broad population of patients
undergoing PCI with second-generation DES [6]. In parallel with the
randomized TWENTE trial, we performed a registry which assessed
patients who also underwent PCI with second-generation DES and
were eligible for enrollment in the randomized trial but were not
enrolled for various reasons [7]. The pooled population of the random-
ized trial and the non-enrolled registry represent a consecutive series
of patientswith stable angina or non-ST-elevationmyocardial infarction
886 H. Sen et al. / International Journal of Cardiology 176 (2014) 885–890(MI)who underwent a PCI at Thoraxcentrum Twente during a period of
26 months. A total of 11% of patients of the TWENTE trial and 17% of the
non-enrolled TWENTE registry had a history of CABG.
In the present study, we analyzed the pooled population of the
TWENTE trial and non-enrolled TWENTE registry to assess the impact
of previous CABG on individual clinical endpoints following PCI with
second-generation DES. In addition, we investigated the potential
impact of lesion location (i.e. in bypass graft versus native coronary
artery) on clinical outcome.2. Methods
2.1. Study design and patient population
We performed a pooled analysis of the prospective TWENTE trial and TWENTE
non-enrolled registry. We analyzed 1709 consecutive patients, undergoing PCI with
second-generation DES for stable angina or non-ST-elevation acute coronary syndromes
(Non-ST-ACS) at Thoraxcentrum Twente in Enschede, The Netherlands. Patients were
treated between June 2008 and August 2010. To compare baseline characteristics and
clinical outcome between patients with previous CABG versus patients without previous
CABG, the patient population was sub-divided, based on history of CABG. Details of the
randomized TWENTE trial have previously been reported [6]. In brief, TWENTE
(ClinicalTrials.gov NCT01066650) is a randomized, prospective, controlled, patient-
blindedDES trial, comparing Resolute ZES and XienceV EES stents after 1:1 randomization
in 1391 patients. Patients with stable angina or non-ST-ACS were eligible, and few exclu-
sion criteriawere applied [6]. Thenon-enrolled TWENTE registry has also been reported in
detail; it included 318 eligible patients who were not enrolled during the course of the
randomized TWENTE trial [7].2.2. Intervention, medication, electrocardiography, and laboratory testing
Five experienced interventional cardiologists, of whom each had individual experi-
ence of at least 4000 PCI procedures as a ﬁrst operator, performed all PCI procedures by
the use of standard techniques. Pharmacological therapy before, during, and after PCI as
well as systematic laboratory testing and ECG assessment have previously been described
and did not differ between the TWENTE trial and TWENTE non-enrolled registry [6].
Angiographic analyses were performed ofﬂine at Thoraxcentrum Twente.2.3. Deﬁnitions of clinical endpoints
Deﬁnitions of clinical endpoints have been fully described in the main report on the
randomized TWENTE trial [6]. In general, the deﬁnitions of theAcademic Research Consor-
tium (ARC) were applied [8,9]. Cardiac death was deﬁned as any death due to proximate
cardiac cause, unwitnessed death and death of unknown cause, and all procedure-related
deaths, including those related to concomitant treatment.
Myocardial infarction (MI) was deﬁned by any creatine kinase concentration of more
than twice the upper limit of normal with elevated conﬁrmatory cardiac biomarkers [9].
Further classiﬁcation and location of MI have been previously described [6]. Target
vessel-relatedMIwas related to the target vessel or could not be related to another vessel.
Target vessel and target lesion revascularization (TVR and TLR)were deﬁned as any repeat
coronary revascularization of the target vessel or target lesion by re-PCI or surgery. Stent
thrombosis was deﬁned according to ARC [8].2.4. Data acquisition and follow-up
In-hospital adverse events were recorded prior to discharge. One-year follow-up data
after PCI of all patients were obtained at visits in outpatient clinics or, if not feasible, by
telephone follow-up or questionnaire. For any event trigger, all clinical information avail-
able from the referring cardiologist, general practitioner, and hospital involved was gath-
ered. The adjudication of adverse clinical events was performed by an independent CRO
(Cardialysis, Rotterdam, The Netherlands).2.5. Statistical analysis
Data analysis was performed with the Statistical Package for Social Sciences (SPSS;
version 17, SPSS Inc., Chicago, IL). Data were reported as frequencies and percentages
for dichotomous and categorical variables and asmean± standard deviation for continu-
ous variables. The chi-square test and the Fisher's exact test were used to compare
frequencies as appropriate. The Student's t-test was used to compare normally distributed
continuous variables. The Kaplan–Meier method was used to calculate the time to clinical
endpoints and the Log-rank test was used to compare between-group differences.
A two-sided P value b 0.05 was considered statistically signiﬁcant.3. Results
3.1. Characteristics of patients, lesion, and PCI procedures
Of all 1709 patients, 202 (11.8%) had a history of CABG (Table 1).
These patients were older (68.5 ± 9.4 vs. 64.1 ± 10.7 years), more
often males (79.7% vs. 71.1%), and suffered more often from diabetes
(28.7% vs. 20.9%), chronic renal failure (6.4% vs. 3.1%), and heart failure
(6.9% vs. 3.2%) than patients without a history of CABG. In addition,
patients with previous CABG had more often a history of MI (40.6% vs.
33.5%) and PCI (40.1% vs. 19.8%). Despite the – on average – higher
cardiovascular risk proﬁle, patients with previous CABG were more
often treated for stable angina, rather than for acute coronary syndromes
(55.0% vs. 47.4%; Table 1). At discharge, patients with previous CABG did
not differ from patients without previous CABG in use of statins (90% vs.
86%, P = 0.18), ACE inhibitors (31% vs. 29%, P =0.42), beta blockers
(82% vs. 82%, P = 0.85), acetylsalicylic acid (99% vs. 99%, P = 0.76), and
thienopyridine (99% vs. 99.5%, P = 0.13) (Table 1).
Patients with previous CABG versus patients without history of
previous CABG differed in several lesion characteristics and procedural
details (Table 1), including more index PCI for in-stent restenosis
(11.4% vs. 5.9%) and type C lesions (62.4% vs. 48.7%) — a difference
that was mainly related to bypass graft lesions. Patients with previous
CABG less often underwent PCI of lesions in left anterior descending
coronary arteries (17.3% vs. 55.4%).
Of the 202 patients with previous CABG, 65 (32.2%) patients were
treated for at least one lesion in a bypass graft, of which 62 (95.4%)
were located in saphenous vein grafts and 3 (4.6%) in arterial grafts.
PCI was performed on average 11.2 ± 8.5 years after CABG. Time
between CABG and PCI differed signiﬁcantly between patients treated
for bypass lesions versus native coronary lesions only (9.6 ± 8.6 vs.
14.3 ± 7.5 months, P b 0.001). Fig. 1 shows the distribution of patients
in time intervals from CABG to index PCI for 65 patients with PCI in graft
lesions versus 132 patients with PCI in native coronary lesions only.
3.2. Clinical outcome
One-year follow-up was available in 1703 (99.6%) patients. Table 2
shows the clinical outcome of patients with previous CABG versus
patients without previous CABG. The only difference was a higher TVR
rate in patients with previous CABG (9.4% vs. 2.3%, P b 0.001) (Fig. 2A)
and explains the signiﬁcantly higher rate of dual anti-platelet therapy
continuation beyond 12 months (12.7% vs. 4.5%, P b 0.001) in these
patients.
Table 3 presents the outcome of the 202 patients with previous
CABG; it shows that the TVR rate was much higher in 65 patients who
were treated for bypass graft lesions than in the 137 patients who were
treated for native coronary lesions only (18.5% vs. 5.1%, p = 0.002)
(Fig. 2B).
As shown in Table 4, among 1638 patients who underwent PCI for
the treatment of native coronary lesions only (irrespective of a history
of CABG), there was a non-signiﬁcant difference in TVR between
patients with previous CABG versus patients without previous CABG
(5.1% vs. 2.3%, P = 0.08).
4. Discussion
4.1. Major ﬁndings
In this pooled analysis of 1709 consecutive patients of the prospec-
tive TWENTE trial and the TWENTE non-enrolled registry, patients
with previous CABG had a 4-fold higher 1-year risk of TVR after PCI
than patients without previous CABG. Differences in the incidence of
cardiac death, target vessel-related MI, and stent thrombosis showed
the same trend, but were non-signiﬁcant. Within patients who
underwent PCI for native coronary lesions only, there also appeared to
Table 1
Baseline characteristics of patients and procedures of patients with versus without
previous CABG.
Patients
with CABG
in history
(N = 202)
Patients
without CABG
in history
(N = 1507)
P value
Age (yrs) 68.5 ± 9.4 64.1 ± 10.7 b0.001
Men 161 (79.7) 1072 (71.1) 0.011
Diabetes mellitus (any) 58 (28.7) 315 (20.9) 0.012
Chronic renal failure⁎ 13 (6.4) 46 (3.1) 0.013
Arterial hypertension 113 (55.9) 845 (56.1) 0.972
Hypercholesterolemia 143/199 (71.9) 853/1476 (57.8) b0.001
Current smoker 22 (10.9) 388 (25.7) b0.001
Family history of CAD 108/181 (59.7) 734/1403 (52.3) 0.062
Myocardial infarction (any) 82 (40.6) 505 (33.5) 0.046
Previous PCI 81 (40.1) 299 (19.8) b0.001
Clinical characteristic 0.023
Stable angina pectoris 111 (55.0) 714 (47.4)
Acute coronary syndrome 91 (45.0) 793 (52.6)
Unstable angina 51 (25.2) 358 (23.8)
Non-ST-elevation MI 40 (19.8) 435 (28.9)
Left ventricular ejection
fraction b 30%†
10/144 (6.9) 35/1106 (3.2) 0.022
Multivessel treatment 52 (25.7) 345 (22.9) 0.368
Total no lesions treated per patient 0.381
One lesion treated 133 (65.8) 927 (61.5)
Two lesions treated 49 (24.3) 436 (28.9)
Three of more lesions treated 20 (9.9) 144 (9.6)
At least one CTO 12 (5.9) 111 (7.4) 0.462
At least one bifurcation 36 (17.8) 409 (27.1) 0.005
At least one in-stent restenosis 23 (11.4) 89 (5.9) 0.003
Postdilatation 177 (87.6) 1323 (87.8) 0.946
Target coronary artery
Left main‡ 35 (17.3) 34 (2.3) b0.001
Left anterior descending 35 (17.3) 835 (55.4) b0.001
Left circumﬂex 60 (29.7) 461 (30.6) 0.797
Right coronary artery 66 (32.7) 550 (36.5) 0.288
Bypass graft 65 (32.2) – b0.001
ACC-AHA lesion class 0.003
A 5 (2.5) 70 (4.6)
B1 22 (10.9) 240 (15.9)
B2 49 (24.3) 463 (30.7)
C 126 (62.4) 734 (48.7)
Medication at discharge
Statin 180/201 (89.6) 1279/1485 (86.1) 0.182
Ace-inhibitor 63/201 (31.3) 425/1486 (28.6) 0.421
Beta-blocker 164/201 (81.6) 1219/1484 (82.1) 0.848
Acetylsalicylic acid 199 (98.5) 1486 (98.6) 0.757
Thienopyridine 199 (98.5) 1497/1505 (99.5) 0.132
DAPT 196 (97.0) 1479 (98.1) 0.281
Medication at 1-year§ N = 142 N = 1216
Acetylsalicylic acid 130 (91.5) 1133 (93.2) 0.473
Thienopyridine b0.001
Stopped after 1 year 118 (83.1) 1130 (92.9)
Less than 1 year 4 (2.8) 17 (1.4)
Continued after 1 year 20 (14.1) 69 (5.7)
Dual anti-platelet therapy b0.001
Stopped after 1 year 109 (76.8) 1062 (87.3)
Less than 1 year 15 (10.6) 99 (8.1)
Continued after 1 year 18 (12.7) 55 (4.5)
Data are number (%) or mean (SD). CAD = coronary artery disease. PCI = percutaneous
coronary intervention. CABG = coronary artery bypass grafting. MI = myocardial infarc-
tion. CTO = chronic total occlusion.
⁎ Chronic renal failure was deﬁned by serum creatinine level ≥ 130 μmol/L.
† Left ventricular ejection fraction was assessed with ultrasound, MRI or LV
angiography.
‡ 2/35 PCI in left main stems were performed for unprotected left main disease.
§ Based on data from the randomized TWENTE trial. No data are available for patients
from the Non-enrolled TWENTE registry.
Fig. 1. PCI per time interval from CABG to index PCI in patients with previous CABG. The
distribution of patients in time intervals fromCABG to index PCI for the two patient groups
(65 patients with PCI in graft lesions vs. 132 patients with PCI in native coronary lesions
only). Analysis based on 197/202 patients with knowledge of exact time interval.
Among the 17 pts. who underwent PCI in native coronary vessels during 0–1 year from
previous CABG, 9 were treated in grafted and 8 in ungrafted coronary arteries.
Table 2
Clinical endpoints at 1-year follow-up of patients with versus without previous CABG.
Patients with
CABG in history
(N = 202)
Patients without
CABG in history
(N = 1.501)
P value
Death
Any cause 7 (3.5) 29 (1.9) 0.185
Cardiac cause 5 (2.5) 17 (1.1) 0.171
Target vessel-related MI
Any 13 (6.4) 66 (4.4) 0.196
Clinically indicated TVR
Any 19 (9.4) 35 (2.3) b0.001
Percutaneous 18 (8.9) 27 (1.8) b0.001
Surgical 1 (0.5) 8 (0.5) 1.0
Clinically indicated TLR
Any 13 (6.4) 25 (1.7) b0.001
Percutaneous 13 (6.4) 18 (1.2) b0.001
Surgical 0 7 (0.5) 1.0
Deﬁnite ST
(0–360 days)
0 4 (0.3) 1.0
Probable ST
(0–360 days)
3 (1.5) 8 (0.5) 0.133
ST (0–360 days)
Possible 3 (1.5) 6 (0.4) 0.080
Deﬁnite or probable 3 (1.5) 12 (0.8) 0.408
Deﬁnite, probable or
possible
6 (3.0) 18 (1.2) 0.056
Data are number of patients (%). MI = myocardial infarction. TVR = target vessel
revascularization. TLR = target lesion revascularization. ST = stent thrombosis.
887H. Sen et al. / International Journal of Cardiology 176 (2014) 885–890be a difference in TVR rate between patients with previous CABG versus
patients without previous CABG, which was almost signiﬁcant. Among
patients with previous CABG, the TVR rate was 3.5-fold higher inpatients treated for target lesions in bypass grafts. Thus, the increased
TVR risk of patients with prior CABG is mainly related to PCI performed
in vein grafts.4.2. Comparison with previous studies
In the present study, 11.8% of patients had a previous CABG
(on average 11.2 years before PCI), which is similar to or higher
than several randomized DES trials where 7% to 11.5% had prior
CABGprocedures [10–14]. During the last decades, there has been an in-
crease in patients with previous CABG, who ultimately required addi-
tional coronary revascularization procedures. Some factors may have
contributed to this development. For instance, the aging of populations
with a western lifestyle has increased the likelihood of developing very
Fig. 2.Target vessel revascularization during follow-upof 1 year. A: Kaplan–Meier cumulative incidence curves at 1-year for target vessel revascularization for patientswith versuswithout
prior CABG. B: Kaplan–Meier cumulative incidence curves at 1-year for target vessel revascularization for patientswith prior CABG treated for graft lesions versus lesions innative coronary
vessels only.
888 H. Sen et al. / International Journal of Cardiology 176 (2014) 885–890advanced stages of coronary disease and graft failure [1]. In addition,
coronary revascularization techniques have been spread over time,
leading to a substantial increase in the accessibility of coronary revascu-
larization procedures [15].Table 3
Clinical outcome at 1-year of CABGpatients treated for graft lesions versus native coronary
lesions only.
Graft lesions
(N = 65)
Native vessels
only (N = 137)
P value
Death
Any cause 3 (4.6) 4 (2.9) 0.538
Cardiac cause 1 (1.5) 4 (2.9) 0.555
Target vessel-related MI
Any 6 (9.2) 7 (5.1) 0.265
Clinically indicated TVR
Any 12 (18.5) 7 (5.1) 0.002
Percutaneous 12 (18.5) 6 (4.4) 0.001
Surgical 0 1 (0.7) 0.490
Clinically indicated TLR
Any 10 (15.4) 3 (2.2) b0.001
Percutaneous 10 (15.4) 3 (2.2) b0.001
Surgical – – –
Probable ST (0–360 days) 1 (1.5) 2 (1.5) 0.966
ST (0–360 days)
Possible – 3 (2.2) 0.229
Deﬁnite, probable or possible 1 (1.5) 5 (3.6) 0.409
Data are number of patients (%). MI = myocardial infarction. TVR = target vessel
revascularization. TLR = target lesion revascularization. ST = stent thrombosis.Angiographic studies have shown that 10 years from CABG approx-
imately 75% of vein grafts are occluded or severely diseased [16,17]. The
attrition of vein grafts with the formation of intimal hyperplasia is
promoted by the exposure of the thin-walled conduit to the higherTable 4
Clinical outcome after 1 year of patients treated for lesions in native coronary vessels only
comparing patients with versus without previous CABG.
Native vessels
CABG
(N = 137)
Native vessels
non-CABG
(N = 1501)
P value
Death
Any cause 4 (2.9) 29 (1.9) 0.350
Cardiac cause 4 (2.9) 17 (1.1) 0.092
Target vessel-related MI
Any 7 (5.1) 66 (4.4) 0.665
Clinically indicated TVR
Any 7 (5.1) 35 (2.3) 0.080
Percutaneous 6 (4.4) 27 (1.8) 0.052
Surgical 1 (0.7) 8 (0.5) 0.545
Clinically indicated TLR
Any 3 (2.2) 25 (1.7) 0.504
Percutaneous 3 (2.2) 18 (1.2) 0.412
Surgical – 7 (0.5) 1.000
Probable ST (0–360 days) 2 (2.2) 8 (0.5) 0.201
ST (0–360 days)
Possible 3 (2.2) 6 (0.4) 0.033
Deﬁnite, probable or possible 5 (3.6) 18 (1.2) 0.037
Data are number of patients (%). MI = myocardial infarction. TVR = target vesse
revascularization. TLR = target lesion revascularization. ST = stent thrombosis.,
l
889H. Sen et al. / International Journal of Cardiology 176 (2014) 885–890and pulsatile pressure in the systemic circulation [18], the compliance
mismatch between vein graft and native coronary arteries, and early
endothelial damage along suture lines or due to intraoperative handling
of vein graft material. Migration of vascular smooth muscle cells,
sustained collagen proliferation, and lipid deposition result in the
accelerated formation of more friable atherosclerotic plaques [19].
While there are several similarities in the predisposing factors and the
general process of atheroma formation between vein graft and native
coronary atheromas, vein graft atheromas aremore diffuse and concen-
tric, less calciﬁed, and often have poorly developed or absent ﬁbrous
caps [19,20]. As a consequence of the higher friability of the lesions,
PCI in vein grafts are associated with a higher risk of plaque emboliza-
tion, no-reﬂow during PCI, and TVR, as compared to PCI in native coro-
nary arteries [21,22].
PCIs of arterial grafts aremore rare and are generally required after a
shorter time interval from CABG, as arterial graft lesions are often the
result of neo-intimal hyperplasia secondary to a vascular trauma during
the preparation of a graft or anastomosis [15]. In addition, the proximal
segments of grafted native coronary arteries (i.e. proximal to the
anastomosis) often show an increased disease progression as a result
of the reduced ﬂow through these segments [23,24]. On the other
hand, as a result of a general progression of atherosclerosis in the native
coronary vasculature, native vessels may develop signiﬁcant lesions
distal to the anastomosis of a graft [15].
In our present study, patients with STEMI were not assessed, as this
subset of PCI patients was not considered for enrollment in the TWENTE
trial [6]. However, the rate of STEMI patients with previous CABG is
relatively low [25]. In a large US registry, for instance, only 6%
of STEMI patients had a previous CABG; and in the randomized
APEX-AMI trial 2.2% of all 5,745 STEMI patients had a history of CABG.
STEMI patients with previous CABG were older and had more comor-
bidities (e.g. more diabetes), which may have contributed to a higher
mortality (12% vs. 5%, P b 0.001; in APEX-AMI trial) [26]. The mortality
of STEMI patients with CABG was particularly high if the culprit vessel
was a bypass graft rather than a native coronary artery (19% vs. 6%,
P = 0.03) [26].
The majority of our patients with previous CABG underwent PCI for
target lesions in native coronary arteries (68%) rather than bypass grafts
(32%). This relation is quite similar to that of other studies, in which
patients with previous CABG underwent PCI in 56% to 63% for treatment
of lesions in native coronary arteries [3,4,27,28]. In a study among 91
consecutive patients with previous CABG who were treated by PCI
with BMS or ﬁrst-generation DES, a repeat revascularization rate of
10.9% was found [3]. Despite the use of second-generation DES in our
present study, we still found a TVR rate of 9.4%.
In another study, 161 patients with previous CABG who were treat-
ed between September 2005 and April 2008with PCI using BMS or DES
were analyzed. In that study, a higher incidence of TVR was the only
difference in individual clinical endpoints between patients treated for
graft versus native coronary lesions (15.0% vs. 4.9%, after mean follow-
up of 13 months) [4]. In addition, previous studies have demonstrated
a clinical beneﬁt of PCI with DES versus BMS in vein grafts [21]. Our
data show that, despite the use of contemporary second-generation
DES with biocompatible durable coatings, the discrepancy in TVR
between patients treated for graft lesions versus native coronary lesions
remained similar (19% vs. 5%, at 1-year follow-up). Data from the large
National Cardiovascular Data Registry CathPCI Registry have shown that
the in-hospital mortality was higher in patients with previous CABG if
they were treated for graft lesions (OR: 1.22, 95% CI: 1.12–1.32,
P b 0.001) [27]. However, CABG with arterial grafting was associated
with lower rates of major adverse cardiac events [29].
4.3. Clinical implications
If a secondary revascularization is required in patients with previous
CABG, many patients prefer to undergo a PCI rather than a redo-CABG[30], as the redo-CABG is associated with a higher mortality than the
initial CABG [31]. Our data conﬁrm that PCI with contemporary DES is
feasible and safe in patients with previous CABG. But despite the use
of modern DES, PCI of bypass graft lesions is still associated with a
much higher TVR rate. Therefore, if PCI of both native coronary and
corresponding graft lesions is feasible with a similar resource utilization
and chance of lesion success, a thorough heart team discussion on
clinical risk may help to choose the most appropriate therapeutic
strategy.
5. Study limitations
Because of its post hoc nature, the results of the present study should
be considered hypothesis generating. The TWENTE trial as well as the
non-enrolled TWENTE registry assessed patients with limited exclusion
criteria but no acute STEMI; therefore, our results may not be extrapo-
lated to the setting of STEMI [6,7]. In addition, follow-up of this pooled
patient population is limited to 1 year [32]. A longer-term follow-up
may be of interest to assess potential differences in long-termmortality
and morbidity between patients with previous CABG versus patients
without previous CABG.
6. Conclusions
Patientswith previous CABGwere older and had a higher prevalence
of diabetes, but the safety proﬁle of PCI with contemporary second-
generation DES was favorable in this group of patients. Nevertheless,
their overall TVR rate was still higher than that of patients without a
history of CABG, and it was driven by a higher TVR rate in degenerated
vein grafts. Following PCI of native coronary arteries, there was no
signiﬁcant difference between patients with previous CABG versus
patients without previous CABG.
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